|
|
Volumn 18, Issue 2, 2011, Pages 73-
|
|
New trends in primary systemic therapy for breast cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AROMATASE INHIBITOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTROGEN RECEPTOR;
GONADORELIN DERIVATIVE;
KI 67 ANTIGEN;
PROGESTERONE RECEPTOR;
TAMOXIFEN;
TRASTUZUMAB;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER HORMONE THERAPY;
CANCER RESISTANCE;
CANCER SURVIVAL;
DISEASE FREE SURVIVAL;
DRUG RESPONSE;
EDITORIAL;
HUMAN;
IMMUNOHISTOCHEMISTRY;
MOLECULARLY TARGETED THERAPY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGNOSIS;
SYSTEMIC THERAPY;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
PERIODICALS AS TOPIC;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
|
|
EID: 79956365082
PISSN: 13406868
EISSN: 18804233
Source Type: Journal
DOI: 10.1007/s12282-010-0243-4 Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|
